Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Progenics Pharmaceuticals Inc. PGNX

Healthcare Biotechnology

"Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate... see more

Add To Watchlist

Recent & Breaking News (NDAQ:PGNX)

Progenics Schedules Investor Conference Call Following FDA Advisory Committee

GlobeNewswire June 12, 2014

Progenics Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Consider and Provide Recommendations Regarding Peripherally-Acting Opioid Receptor Antagonists

GlobeNewswire June 11, 2014

Progenics Pharmaceuticals CEO Mark Baker to Present at Jefferies Global Healthcare Conference

GlobeNewswire June 2, 2014

Progenics Pharmaceuticals' PSMA ADC Data Selected for Poster Highlight Presentation at ASCO 2014

GlobeNewswire May 30, 2014

Progenics Pharmaceuticals Announces First Quarter 2014 Financial Results

GlobeNewswire May 9, 2014

Progenics Pharmaceuticals Sets First Quarter 2014 Financial Results Call for May 9

GlobeNewswire May 1, 2014

Progenics Pharmaceuticals Announces the Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC

GlobeNewswire April 24, 2014

Salix Pharmaceuticals and Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand the Use of RELISTOR in Chronic Non-Cancer Pain by the European Medicines Agency

Business Wire April 22, 2014

Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 13th Annual Needham Healthcare Conference

GlobeNewswire April 7, 2014

Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications

GlobeNewswire April 1, 2014

Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa

PR Newswire March 21, 2014

Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2013 Financial Results and Initiates Clinical Development of Small Molecule Targeted Therapeutic

GlobeNewswire March 13, 2014

Progenics Pharmaceuticals Sets 4Q and Year-End 2013 Financial Results Call for March 13

GlobeNewswire March 10, 2014

Progenics Pharmaceuticals Sets 1Q 2014 Financial Results Call for March 13

GlobeNewswire March 4, 2014

DryShips Braces for More Losses in Slowly Recovering Economy

Accesswire February 24, 2014

Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

GlobeNewswire February 21, 2014

Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire February 20, 2014

Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 16th Annual BIO CEO & Investor Conference

Globe Newswire February 6, 2014

Five Star Equities Issues New Research Reports on GEVO, MTOR, PGNX and PRTA

Accesswire February 3, 2014

Progenics 1404 Imaging Agent Shows High Accuracy in Detecting Cancer Within the Prostate Gland in Interim Analysis of Phase 2 Study

Globe Newswire January 30, 2014